Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Transitional Cell Cancer of Renal Pelvis and Ureter 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × padeliporfin × Clear all
NCT04620239 2026-02-04

UCM301

Steba Biotech S.A.

Phase 3 Recruiting
100 enrolled
Genitourinary

Transitional Cell Cancer of Renal Pelvis and Ureter

Data powered by HemOnc (CC BY 4.0) Colophon âš¡